Chargement en cours...
Phase I study of the combination of losoxantrone and cyclophosphamide in patients with refractory solid tumours
Losoxantrone is a DNA intercalator that was developed with the potential to replace anthracyclines. The recommended single agent dose of losoxantrone is 50 mg m(−2) every 3 weeks. We conducted a phase I study of losoxantrone and a fixed dose of cyclophosphamide on a q3 weekly schedule. Forty-nine pa...
Enregistré dans:
| Auteurs principaux: | , , , |
|---|---|
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Nature Publishing Group
2002
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2375276/ https://ncbi.nlm.nih.gov/pubmed/11870533 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6600123 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|